Zoetis

ZTS Healthcare & Pharma 4/10 Medium Risk

4/10

— 3 → 4 over 22 weeks

Sector avg: 3.1/10

Zoetis has $5.6B in scheduled debt maturities. Notably, the entire $5.6B maturity schedule falls within five years, creating a concentrated refinancing window. DebtCanary scores ZTS at 4/10, indicating moderate refinancing pressure.

Maturity Schedule

As of 2026-03-31 (latest SEC filing with maturity data). Debt actions taken after this date will only appear once SEC processes the relevant XBRL filing.

Period	Amount Due	% of Total
Year 1 (0-12 months)	$750M	13.4%
Year 2 (12-24 months)	$1.4B	24.1%
Year 3 (24-36 months)	$2.0B	35.7%
Year 4 (36-48 months)	$750M	13.4%
Year 5 (48-60 months)	$750M	13.4%
Beyond 5 Years	N/A	N/A
Total Scheduled Maturities	$5.6B	100.0%

Key Metrics

Total Long-Term Debt

N/A

Near-Term (12mo)

$750M

Interest Coverage

N/A

Debt/Equity

1.73

Cash Coverage

2.59x

Operating Income

N/A

How This Score Was Computed

Weighted average of 3 scored components (raw 3.67, rounded to 4). Weights of skipped components are redistributed proportionally among those scored.

Component	Value	Sub-Score	Weight Used
Near-Term Maturity Concentration Show calculation Year-1 maturities / Total scheduled maturities Year-1 maturities: $750M Total scheduled maturities: $5.6B	13.4%	3/10	40%
Interest Coverage Ratio Operating income was not reported in the latest 10-K.	N/A	—	not scored
Debt-to-Equity Ratio Show calculation Long-term debt / Stockholders' equity Long-term debt: $5.6B Stockholders' equity: $3.2B No balance-sheet long-term debt figure was reported; total scheduled maturities used as the debt proxy.	1.73	5/10	33%
Cash Coverage of Near-Term Debt Show calculation Cash & equivalents / Debt due within 12 months Cash & equivalents: $1.9B Near-term debt: $750M	2.59x	3/10	27%
Cash Runway Only scored when a company is burning cash. Operating cash flow is positive (or unreported), so runway isn't a constraint.	N/A	—	not scored

"Weight Used" shows each component's share after the weights of unscored components are redistributed. Full thresholds and formulas are on the methodology page.

Recent SEC Filings

Material disclosures from Zoetis's most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date	Form	Details
2026-05-22	8-K	Officer / Director Change, Shareholder Vote
2026-05-20	8-K	Reg FD Disclosure
2026-05-07	10-Q	Quarterly report
2026-05-07	8-K	Earnings Results
2026-04-08	DEFA14A	Additional proxy materials
2026-04-08	DEF 14A	Proxy statement
2026-02-12	10-K	Annual report
2026-02-12	8-K	Earnings Results

Related Companies

Johnson & Johnson

JNJ

1/10

Debt: $41.4B 12mo: $2.0B

Pfizer

PFE

5/10

Debt: N/A 12mo: $3.9B

AbbVie

ABBV

4/10

Debt: $64.5B 12mo: $6.0B

Merck &

MRK

4/10

Debt: $49.1B 12mo: $2.6B

Eli Lilly

LLY

4/10

Debt: $29.5B 12mo: N/A

Bristol Myers Squibb

BMY

5/10

Debt: $44.1B 12mo: $2.0B

Amgen

AMGN

5/10

Debt: $57.3B 12mo: $4.6B

Gilead Sciences

GILD

2/10

Debt: $22.2B 12mo: $1.3B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2026-03-31. Filing date: 2026-05-07. Data last fetched: 2026-07-26. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Zoetis →